Jpmorgan Chase & CO Inhibrx, Inc. Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$32.76 - $39.56 $695,756 - $840,175	21,238 Added 41.22%	72,764 $2.54 Million
Q4 2023 Feb 12, 2024	SELL	$14.5 - $38.0 $4.62 Million - $12.1 Million	-318,459 Reduced 86.07%	51,526 $1.96 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $48,636 - $81,245	3,088 Added 0.84%	369,985 $6.79 Million
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $5.54 Million - $9.09 Million	326,919 Added 817.75%	366,897 $9.52 Million
Q1 2023 May 18, 2023	BUY	$18.45 - $27.14 $731,985 - $1.08 Million	39,674 Added 13050.66%	39,978 $754,000
Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $589,791 - $867,584	-31,967 Reduced 99.06%	304 $5,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $69,580 - $114,921	3,448 Added 11.96%	32,271 $795,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $40,391 - $86,258	3,488 Added 13.77%	28,823 $517,000
Q2 2022 Aug 11, 2022	BUY	$8.52 - $25.26 $14,662 - $43,472	1,721 Added 7.29%	25,335 $288,000
Q1 2022 May 11, 2022	SELL	$19.89 - $43.18 $749,892 - $1.63 Million	-37,702 Reduced 61.49%	23,614 $527,000
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $987,208 - $1.7 Million	36,905 Added 151.18%	61,316 $2.68 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $614,668 - $922,979	24,411 New	24,411 $813,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $580M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.